Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

An Avastin Loophole: Hamburg Could Decide To Retain Approval During Confirmatory Trial

This article was originally published in The Pink Sheet Daily

Executive Summary

Even if the commissioner determines the grounds for withdrawing Avastin's accelerated approval in breast cancer have been met, she could decide to retain the claim while Genentech conducts additional confirmatory trials, the hearing notice explains.
Advertisement

Related Content

Oncology Drug Applications Migrate As Part Of FDA's Reorganization Of OODP
Oncology Drug Applications Migrate As Part Of FDA's Reorganization Of OOP
Less Than Half Of ODAC Members Will Participate In Avastin Hearing
Genentech Gets OK To Discuss Confirmatory Study Plans At Avastin Hearing
Accelerated Approval Program’s Future Is On The Line At Avastin Hearing
Genentech Appeals To FDA's "Regulatory Flexibility"
ODAC Will Have Bigger Role At Avastin Hearing Than Previously Described
Avastin Hearing: Genentech, CDER Dispute Relevance Of Second-Line Breast Cancer Data
Avastin Data, Policy Implications Warrant Hearing On Breast Cancer Use, Genentech Tells FDA
Avastin Data, Policy Implications Warrant Hearing On Breast Cancer Use, Genentech Tells FDA

Topics

Advertisement
UsernamePublicRestriction

Register

PS072337

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel